Next Article in Journal
Direct Activation of Ribosome-Associated Double-Stranded RNA-Dependent Protein Kinase (PKR) by Deoxynivalenol, Anisomycin and Ricin: A New Model for Ribotoxic Stress Response Induction
Previous Article in Journal
The Fate of Microcystins in the Environment and Challenges for Monitoring
Previous Article in Special Issue
Non-Native (Exotic) Snake Envenomations in the U.S., 2005–2011
 
 
Review

Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms

1
Structural and Functional Venomics Lab, Instituto de Biomedicina de Valencia (CSIC), Valencia 46010, Spain
2
Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica
*
Authors to whom correspondence should be addressed.
Toxins 2014, 6(12), 3388-3405; https://doi.org/10.3390/toxins6123388
Received: 8 November 2014 / Revised: 3 December 2014 / Accepted: 9 December 2014 / Published: 15 December 2014
(This article belongs to the Special Issue Antivenom and Venom Therapeutics)
Snakebite envenoming represents a neglected tropical disease that has a heavy public health impact worldwide, mostly affecting poor people involved in agricultural activities in Africa, Asia, Latin America and Oceania. A key issue that complicates the treatment of snakebite envenomings is the poor availability of the only validated treatment for this disease, antivenoms. Antivenoms can be an efficacious treatment for snakebite envenoming, provided they are safe, effective, affordable, accessible and administered appropriately. The shortage of antivenoms in various regions, particularly in Sub-Saharan Africa and some parts of Asia, can be significantly alleviated by optimizing the use of current antivenoms and by the generation of novel polyspecific antivenoms having a wide spectrum of efficacy. Complementing preclinical testing of antivenom efficacy using in vivo and in vitro functional neutralization assays, developments in venomics and antivenomics are likely to revolutionize the design and preclinical assessment of antivenoms by being able to test new antivenom preparations and to predict their paraspecific neutralization to the level of species-specific toxins. View Full-Text
Keywords: snake venom; snakebite envenoming; antivenom; preclinical venom neutralization assays; venomics; antivenomics snake venom; snakebite envenoming; antivenom; preclinical venom neutralization assays; venomics; antivenomics
Show Figures

Figure 1

MDPI and ACS Style

Calvete, J.J.; Sanz, L.; Pla, D.; Lomonte, B.; Gutiérrez, J.M. Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms. Toxins 2014, 6, 3388-3405. https://doi.org/10.3390/toxins6123388

AMA Style

Calvete JJ, Sanz L, Pla D, Lomonte B, Gutiérrez JM. Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms. Toxins. 2014; 6(12):3388-3405. https://doi.org/10.3390/toxins6123388

Chicago/Turabian Style

Calvete, Juan J., Libia Sanz, Davinia Pla, Bruno Lomonte, and José María Gutiérrez. 2014. "Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms" Toxins 6, no. 12: 3388-3405. https://doi.org/10.3390/toxins6123388

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop